NASDAQ:CYTK
Cytokinetics Stock Earnings Reports
$46.16
+4.54 (+10.91%)
At Close: Feb 14, 2025
Cytokinetics Earnings Calls
Q4 2024
(Upcoming)
Release date | Feb 25, 2025 |
EPS estimate | -$1.29 |
EPS actual | - |
Revenue estimate | 14.262M |
Revenue actual | - |
Expected change | +/- 5.96% |
Q3 2024
Missed
-$1.36 (-7.09%)
Release date | Nov 06, 2024 |
EPS estimate | -$1.27 |
EPS actual | -$1.36 |
EPS Surprise | -7.09% |
Revenue estimate | 2.05M |
Revenue actual | 463K |
Revenue Surprise | -77.41% |
Q2 2024
Missed
-$1.31 (-28.43%)
Release date | Aug 08, 2024 |
EPS estimate | -$1.02 |
EPS actual | -$1.31 |
EPS Surprise | -28.43% |
Revenue estimate | 920K |
Revenue actual | 249K |
Revenue Surprise | -72.93% |
Q1 2024
Missed
-$1.33 (-14.66%)
Release date | May 08, 2024 |
EPS estimate | -$1.16 |
EPS actual | -$1.33 |
EPS Surprise | -14.66% |
Revenue estimate | 900K |
Revenue actual | 835K |
Revenue Surprise | -7.22% |
Last 4 Quarters for Cytokinetics
Below you can see how CYTK performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q1 2024
Missed
Release date | May 08, 2024 |
Fiscal end date | Mar 31, 2024 |
Price on release | $65.27 |
EPS estimate | -$1.16 |
EPS actual | -$1.33 |
EPS surprise | -14.66% |
Date | Price |
---|---|
May 02, 2024 | $64.34 |
May 03, 2024 | $65.27 |
May 06, 2024 | $65.05 |
May 07, 2024 | $65.28 |
May 08, 2024 | $65.27 |
May 09, 2024 | $64.02 |
May 10, 2024 | $62.10 |
May 13, 2024 | $57.89 |
May 14, 2024 | $59.36 |
4 days before | 1.45% |
4 days after | -9.05% |
On release day | -1.92% |
Change in period | -7.74% |
Q2 2024
Missed
Release date | Aug 08, 2024 |
Fiscal end date | Jun 30, 2024 |
Price on release | $54.00 |
EPS estimate | -$1.02 |
EPS actual | -$1.31 |
EPS surprise | -28.43% |
Date | Price |
---|---|
Aug 02, 2024 | $57.14 |
Aug 05, 2024 | $53.43 |
Aug 06, 2024 | $53.54 |
Aug 07, 2024 | $51.22 |
Aug 08, 2024 | $54.00 |
Aug 09, 2024 | $55.79 |
Aug 12, 2024 | $56.18 |
Aug 13, 2024 | $56.07 |
Aug 14, 2024 | $55.88 |
4 days before | -5.50% |
4 days after | 3.48% |
On release day | 3.31% |
Change in period | -2.21% |
Q3 2024
Missed
Release date | Nov 06, 2024 |
Fiscal end date | Sep 30, 2024 |
Price on release | $55.50 |
EPS estimate | -$1.27 |
EPS actual | -$1.36 |
EPS surprise | -7.09% |
Date | Price |
---|---|
Oct 31, 2024 | $51.00 |
Nov 01, 2024 | $51.82 |
Nov 04, 2024 | $51.48 |
Nov 05, 2024 | $52.52 |
Nov 06, 2024 | $55.50 |
Nov 07, 2024 | $55.84 |
Nov 08, 2024 | $57.98 |
Nov 11, 2024 | $58.62 |
Nov 12, 2024 | $56.19 |
4 days before | 8.82% |
4 days after | 1.24% |
On release day | 0.613% |
Change in period | 10.18% |
Q4 2024
(Upcoming)
Release date | Feb 25, 2025 |
Fiscal end date | Dec 30, 2024 |
Price on release | - |
EPS estimate | -$1.29 |
EPS actual | - |
Date | Price |
---|---|
Feb 10, 2025 | $42.21 |
Feb 11, 2025 | $41.56 |
Feb 12, 2025 | $42.18 |
Feb 13, 2025 | $41.62 |
Feb 14, 2025 | $46.16 |
Cytokinetics Earnings Call Transcript Summary of Q3 2024
The call featured updates on clinical development, commercial readiness, and financial performance, alongside future milestones.
Key Developments:
-
Aficamten (Drug Approval Process)
- Submitted a New Drug Application (NDA) to the FDA for aficamten, with a requested priority review (expecting standard review as the base case).
- NDA for aficamten in China accepted for filing via CORXEL (formerly Ji Xing).
- Ongoing commercial preparations for the US market, including a disease awareness campaign.
-
Clinical Data
- Continued presentation of supportive data from SEQUOIA-HCM, establishing aficamten's efficacy in addressing outcomes related to hypertrophic obstructive cardiomyopathy (HCM).
- Analyses indicate significant improvements in exercise capacity and cardiac structure/function.
- Enrollment completed in MAPLE-HCM, with results expected in H1 2025.
-
Cardiology Pipeline Exploration
- Initiation of two new clinical trials:
- COMET-HF: Phase III trial of omecamtiv mecarbil for heart failure with severely reduced ejection fraction.
- AMBER-HFpEF: Phase II trial of CK-586 for heart failure with preserved ejection fraction expected to start this quarter.
- Initiation of two new clinical trials:
-
Emerging Therapies
- CK-089, a skeletal muscle troponin activator, is poised to start clinical development soon.
- Continued emphasis on muscle-directed therapies, with multiple candidates at various stages.
-
Financial Health
- Reported cash and investments of approximately $1.3 billion, down slightly from Q2 2024.
- Total revenues of $0.5 million, reflecting a small increase YoY; R&D expenses increased due to personnel costs related to advancing the pipeline.
- Net loss for the quarter was $160.5 million, slightly higher than the previous year.
Future Milestones:
- Potential US launch of aficamten in 2025, contingent upon FDA approval.
- Expected initiation of additional clinical trials and continued enrollment in ongoing studies.
- Plans for expanding commercial readiness and preparations in European markets.
Investor Considerations:
- Cytokinetics is positioning itself as a leader in specialty cardiology with multiple drug candidates aimed at addressing significant unmet needs.
- With a strong financial foundation and an expanding pipeline, the company aims for sustained growth and value creation for shareholders.
- The upcoming MAPLE-HCM trial results could significantly influence the adoption of aficamten and broader clinical guidelines, impacting market positioning.
The call concluded with optimistic insights into the company's strategic vision and its ongoing efforts to deliver innovative therapies in the cardiology space.
Cytokinetics Earnings History
Earnings Calendar
FAQ
When is the earnings report for CYTK?
Cytokinetics (CYTK) has scheduled its earnings report for Feb 25, 2025 before the markets open.
What is the CYTK price-to-earnings (P/E) ratio?
CYTK P/E ratio as of Feb 14, 2025 (TTM) is -8.61.
What is the CYTK EPS forecast?
The forecasted EPS (Earnings Per Share) for Cytokinetics (CYTK) for the first fiscal quarter 2024 is -$1.29.
What are Cytokinetics's retained earnings?
On its balance sheet, Cytokinetics reported retained earnings of $463.00 thousand for the latest quarter ending Sep 30, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.